TY - JOUR
T1 - Systemic corticosteroids and the risk of venous thromboembolism in patients with severe copd
T2 - A nationwide study of 30, 473 outpatients
AU - Rastoder, Ema
AU - Sivapalan, Pradeesh
AU - Eklöf, Josefin
AU - Saeed, Mohamad Isam
AU - Jordan, Alexander Svorre
AU - Meteran, Howraman
AU - Tønnesen, Louise
AU - Biering-Sørensen, Tor
AU - Løkke, Anders
AU - Seersholm, Niels
AU - Nielsen, Thyge Lynghøj
AU - Carlsen, Jørn
AU - Janner, Julie
AU - Godtfredsen, Nina
AU - Bodtger, Uffe
AU - Laursen, Christian B.
AU - Hilberg, Ole
AU - Knop, Filip Krag
AU - Priemé, Helene
AU - Ingebrigtsen, Truls Sylvan
AU - Gottlieb, Vibeke
AU - Wilcke, Jon Torgny
AU - Jensen, Jens Ulrik Stæhr
N1 - Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021
Y1 - 2021
N2 - Due to frequent exacerbations, many patients with chronic obstructive pulmonary disease (COPD) are exposed to oral corticosteroids (OCS), which may be thrombogenic. We evaluated the risk of hospitalisation with venous thromboembolism (VTE) and death in patients with acute exacerbation of COPD (AECOPD) treated with long and short OCS regimens. In this nationwide cohort study of 30, 473 COPD outpatients treated for AECOPD, we compared the risk of VTE hospitalisation and all-cause mortality within 6 months in OCS dose of > 250 mg vs. ≤ 250 mg. A multivariable Cox proportional hazard regression was used to estimate the risk. The incidence of VTE hospitalisations was 0.23%. A long OCS treatment course was associated with an increased risk of VTE compared to a short course (hazard ratio (HR) 1.69, [95% confidence interval (CI) 1.05 to 2.72], p < 0.031). A higher risk of all-cause mortality was seen in the group of COPD patients treated with a long OCS course (HR 1.71, [95% CI 1.63 to 1.79], p < 0.0001). The risk of reported VTE hospitalisation was higher among AECOPD patients treated with long courses of OCS, but the absolute risk was low, suggesting under-reporting of the condition.
AB - Due to frequent exacerbations, many patients with chronic obstructive pulmonary disease (COPD) are exposed to oral corticosteroids (OCS), which may be thrombogenic. We evaluated the risk of hospitalisation with venous thromboembolism (VTE) and death in patients with acute exacerbation of COPD (AECOPD) treated with long and short OCS regimens. In this nationwide cohort study of 30, 473 COPD outpatients treated for AECOPD, we compared the risk of VTE hospitalisation and all-cause mortality within 6 months in OCS dose of > 250 mg vs. ≤ 250 mg. A multivariable Cox proportional hazard regression was used to estimate the risk. The incidence of VTE hospitalisations was 0.23%. A long OCS treatment course was associated with an increased risk of VTE compared to a short course (hazard ratio (HR) 1.69, [95% confidence interval (CI) 1.05 to 2.72], p < 0.031). A higher risk of all-cause mortality was seen in the group of COPD patients treated with a long OCS course (HR 1.71, [95% CI 1.63 to 1.79], p < 0.0001). The risk of reported VTE hospitalisation was higher among AECOPD patients treated with long courses of OCS, but the absolute risk was low, suggesting under-reporting of the condition.
KW - COPD
KW - Corticosteroids
KW - Exacerbation
KW - Pulmonary embolism
KW - Venous thromboembolism
U2 - 10.3390/biomedicines9080874
DO - 10.3390/biomedicines9080874
M3 - Journal article
C2 - 34440079
AN - SCOPUS:85111629614
VL - 9
JO - Biomedicines
JF - Biomedicines
SN - 2227-9059
IS - 8
M1 - 874
ER -